Myotonic Disorders: Clinical Trials

13 trials for Myotonic Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 active not recruiting, 2 recruiting, 1 enrolling by invitation. 13 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 6, Active not recruiting 2, Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1
Phase 28Completed 3, Active not recruiting 2, Recruiting 2, Enrolling by invitation 1

Follow Myotonic Disorders: new trials by email Literature Review of Myotonic Disorders trials Research Report on Myotonic Disorders

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Calcium Channel Blocker in Myotonic Dystrophy Type 1
Amlodipine - Myotonic Dystrophy 1
Phase 1Not yet recruitingUniversity of Rochester202026-12-072026-11-09
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
SAR446268 - Myotonic Dystrophy
Phase 1 / Phase 2RecruitingSanofi322025-07-232026-09-21
Study of ATX-01 in Participants With DM1
ATX-01, Placebo - Myotonic Dystrophy 1
Phase 1 / Phase 2RecruitingARTHEx Biotech S.L.562024-10-152026-02-10
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
SRP-1003 IV Infusion, Placebo IV Infusion, SRP-1003 SC Injection - Myotonic Dystrophy 1
Phase 1 / Phase 2Enrolling by invitationSarepta Therapeutics, Inc.782024-03-042026-10-05
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
VX-670, Placebo - Myotonic Dystrophy Type 1 (DM1)
Phase 1 / Phase 2Active not recruitingVertex Pharmaceuticals Incorporated472024-02-202026-08-20
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
PGN-EDODM1 for infusion, Placebo - Myotonic Dystrophy 1
Phase 1CompletedPepGen Inc242023-12-122026-02-13
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
DYNE-101, Placebo - Myotonic Dystrophy Type 1 (DM1)
Phase 1 / Phase 2Active not recruitingDyne Therapeutics1272022-09-052026-09-23
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001, Placebo - DM1, Myotonic Dystrophy 1
Phase 1 / Phase 2CompletedAvidity Biosciences, Inc.392021-10-282026-09-28
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
ERX-963, Placebo - Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Phase 1CompletedExpansion Therapeutics, Inc.122019-06-172021-06-23
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
IONIS-DMPKRx, Placebo - Myotonic Dystrophy Type 1
Phase 1 / Phase 2CompletedIonis Pharmaceuticals, Inc.482014-12-012022-12-06
Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
Ranolazine - Myotonia Congenita, Paramyotonia Congenita
Phase 1CompletedOhio State University352014-08-012019-03-05
The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies
Far Infrared Radiation - Muscular Dystrophies
Phase 1UnknownGAAD Medical Research Institute Inc.42008-05-012009-08-17
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
SomatoKine/IPLEX - Myotonic Dystrophy
Phase 1 / Phase 2CompletedUniversity of Rochester172005-11-012012-06-25

Narrower conditions

Myotonic Dystrophy (13)  ·  Muscular Diseases (3)  ·  Muscular Dystrophies (3)  ·  Neuromuscular Diseases (3)  ·  Genetic Diseases, Inborn (2)  ·  Heredodegenerative Disorders, Nervous System (2)  ·  Muscular Disorders, Atrophic (2)  ·  Musculoskeletal Diseases (2)  ·  Nervous System Diseases (2)  ·  Neurodegenerative Diseases (2)  ·  Disorders of Excessive Somnolence (1)  ·  Distal Myopathies (1)  ·  Glycogen Storage Disease Type V (1)  ·  Muscular Dystrophy, Duchenne (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13)  ·  Genetic Diseases, Inborn (11)  ·  Heredodegenerative Disorders, Nervous System (11)  ·  Muscular Disorders, Atrophic (11)  ·  Musculoskeletal Diseases (11)  ·  Nervous System Diseases (11)  ·  Neurodegenerative Diseases (11)  ·  Muscular Diseases (10)  ·  Muscular Dystrophies (10)  ·  Neuromuscular Diseases (10)  ·  Carbohydrate Metabolism, Inborn Errors (1)  ·  Dyssomnias (1)  ·  Genetic Diseases, X-Linked (1)  ·  Glycogen Storage Disease (1)

Interventions

Amlodipine (1)  ·  IGF-I-IGFBP-3 complex (1)  ·  Ranolazine (1)  ·  somatoKine (1)

Sponsors

University of Rochester (2)  ·  ARTHEx Biotech S.L. (1)  ·  Avidity Biosciences, Inc. (1)  ·  Dyne Therapeutics (1)  ·  Expansion Therapeutics, Inc. (1)  ·  GAAD Medical Research Institute Inc. (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  Ohio State University (1)  ·  PepGen Inc (1)  ·  Sanofi (1)  ·  Sarepta Therapeutics, Inc. (1)  ·  Vertex Pharmaceuticals Incorporated (1)

Countries

United States (10)  ·  Canada (6)  ·  United Kingdom (6)  ·  Australia (4)  ·  France (4)  ·  Italy (4)  ·  Germany (3)  ·  Netherlands (3)  ·  Spain (3)  ·  Belgium (2)  ·  New Zealand (2)  ·  Argentina (1)  ·  Israel (1)  ·  Taiwan (1)  ·  Thailand (1)

Top investigators

Elliot Ehrich, MD (1)  ·  Ken Nedd, M.D. (1)  ·  Li Tai, MD (1)  ·  Richard T. Moxley, III, M.D. (1)  ·  William D Arnold, MD (1)

Results publications

PMID 20837825, PMID 30390395, PMID 36804094, PMID 40197813, PMID 41707138

NIH funding

2023 (2), U54NS048843 (1)